TrialNature communications2024

Efficacy of the tetravalent protein COVID-19 vaccine, SCTV01E: a phase 3 double-blind, randomized, placebo-controlled trial.

Ruizhi Zhang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.